VANCOUVER, Nov. 27 /CNW/ - Protox Therapeutics Inc. (TSX-V: PRX - News) today reported financial results and operating highlights for the third quarter ended September 30, 2007. “We have demonstrated significant progress with our PRX302 product development in recent months, including positive Phase 1 results from both the locally recurrent prostate cancer and BPH clinical studies,” said Dr. Fahar Merchant, President and CEO of Protox. “The progress we’ve shown with these clinical trials, together with our strengthened balance sheet from the successful exercise of the November 2005 warrants, puts us in an excellent position to commence multiple Phase 2 trials in 2008, including a Phase 2b trial of PRX321 for the treatment of primary brain cancer.”
